Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-19-026381
Filing Date
2019-10-30
Accepted
2019-10-30 20:02:08
Documents
2
Period of Report
2019-10-30

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 3282
2 EX-24 DOCUMENT attachment1.htm EX-24 2578
  Complete submission text file 0000899243-19-026381.txt   7432
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Issuer) CIK: 0001720725 (see all company filings)

EIN.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 11 LINDA ISLE NEWPORT BEACH CA 92660
Business Address 11 LINDA ISLE NEWPORT BEACH CA 92660 714-299-1864
OYSTER POINT PHARMA I, LLC (Reporting) CIK: 0001769046 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-39112 | Film No.: 191181615